Insider Selling: DexCom (NASDAQ:DXCM) Director Sells $160,000.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $80.00, for a total value of $160,000.00. Following the completion of the transaction, the director owned 50,852 shares in the company, valued at $4,068,160. The trade was a 3.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

Shares of DXCM opened at $83.02 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $31.33 billion, a price-to-earnings ratio of 32.81, a PEG ratio of 1.38 and a beta of 1.41. The stock has a 50 day moving average of $74.20 and a 200 day moving average of $69.62. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $87.85.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The business’s revenue was up 13.1% on a year-over-year basis. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.65 earnings per share for the current year.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BOKF NA boosted its stake in DexCom by 175.7% in the fourth quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock worth $2,344,000 after buying an additional 22,505 shares in the last quarter. Stephens Investment Management Group LLC raised its stake in shares of DexCom by 21.1% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock worth $69,211,000 after acquiring an additional 181,701 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in shares of DexCom during the fourth quarter worth approximately $3,231,000. Goodman Advisory Group LLC bought a new stake in shares of DexCom in the 4th quarter worth approximately $1,293,000. Finally, Employees Retirement System of Texas bought a new stake in shares of DexCom in the 4th quarter worth approximately $37,871,000. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. BTIG Research restated a “buy” rating and set a $90.00 price target (up from $80.00) on shares of DexCom in a research report on Friday, July 31st. Royal Bank Of Canada lifted their price objective on shares of DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Argus increased their target price on shares of DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings cut shares of DexCom from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $95.00 price objective (up from $88.00) on shares of DexCom in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.